×
About 310 results

ALLMedicine™ Leptomeningeal Carcinomatosis Center

Research & Reviews  112 results

Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases
https://clinicaltrials.gov/ct2/show/NCT04545814

Mar 3rd, 2022 - INTERVENTION: Enrolled patients will receive stereotactic radiosurgery (SRS) to all metastases followed by surgical resection of resectable metastases within one to 10 days following SRS. Pathologic specimens will be analyzed, and the patient will...

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-...
https://doi.org/10.1158/1078-0432.CCR-21-1838
Clinical Cancer Research : an Official Journal of the Ame... Chow LQM, Barlesi F et. al.

Jan 30th, 2022 - Central nervous system (CNS) metastases are a prominent cause of morbidity and mortality in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC). The phase 2 ASCEND-7 (NCT02336451) study was specifically designed to assess the effi...

PA- and NP-led Ommaya clinics to manage leptomeningeal carcinomatosis.
https://doi.org/10.1097/01.JAA.0000800264.81721.3d
JAAPA : Official Journal of the American Academy of Physi... Leese EN, Weeder JL et. al.

Nov 14th, 2021 - Physician assistants (PAs) and NPs are essential to quality care delivery. The need to demonstrate value and optimize PA and NP roles in neurology subspecialty clinics is unmet. We outline the development of a PA- and NP-led neuro-oncology procedu...

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511104
Nature Communications; Brastianos PK, Strickland MR et. al.

Oct 14th, 2021 - Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single arm Phase II study of 18 patients with LMD receiving combined ipilimumab and nivolumab unt...

Cauda equina syndrome from intradural metastasis of a non-neural tumor: case report and...
https://doi.org/10.1080/02688697.2021.1958155
British Journal of Neurosurgery; Pagano A, Iaquinandi A et. al.

Aug 1st, 2021 - Cauda equina syndrome (CES) is a challenging condition and it can be caused by variable entities. Leptomeningeal carcinomatosis (LC) is a multifocal seeding of the leptomeninges by malignant cells and it is observed in 1-8% of patients with solid ...

see more →

Clinicaltrials.gov  3 results

Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases
https://clinicaltrials.gov/ct2/show/NCT04545814

Mar 3rd, 2022 - INTERVENTION: Enrolled patients will receive stereotactic radiosurgery (SRS) to all metastases followed by surgical resection of resectable metastases within one to 10 days following SRS. Pathologic specimens will be analyzed, and the patient will...

Pembrolizumab in Patients With Leptomeningeal Disease
https://clinicaltrials.gov/ct2/show/NCT03091478

Jan 26th, 2021 - This is an open-label phase II study of pembrolizumab in patients with advanced solid tumors with leptomeningeal carcinomatosis (LMD). Patients may have received any number of prior therapies for their respective solid tumors, but must not have re...

Expanded Access to ANG1005 for Individual Patients
https://clinicaltrials.gov/ct2/show/NCT02755987

Jun 7th, 2016 - This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1...

see more →

News  9 results

Making Progress Against the Blood-Brain Barrier
https://www.onclive.com/view/making-progress-against-the-blood-brain-barrier

Jan 31st, 2022 - Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier (BBB), a highly restrictive interface between the bloodstream and the brain that prevents most dru...

Management of CNS Metastases in R/R HER2+ mBC
https://www.onclive.com/view/management-of-cns-metastases-in-r-r-her2-mbc

Apr 2nd, 2021 - Transcript: Sarah A. Hurvitz, MD: HER2-positive breast cancer is a unique subtype. Generally the way we look at breast cancer as a whole is, we generally group them based on expression of receptors. There is hormone receptor-positive breast ca...

Improving the Management of EGFR+ NSCLC
https://www.onclive.com/view/improving-the-management-of-egfr-nsclc

Apr 2nd, 2021 - Transcript: Sai-Hong Ignatius Ou, MD, PhD: In summary, the approval of osimertinib as frontline treatment in EGFR-mutant lung cancer has changed the landscape of how we treat EGFR-mutant lung cancer. In the past, we gave drugs that had a fair ...

Ramucirumab/Erlotinib Combo Improves PFS in Frontline EGFR+ NSCLC
https://www.onclive.com/view/ramucirumaberlotinib-combo-improves-pfs-in-frontline-egfr-nsclc

Dec 4th, 2020 - Maura N. Dickler, MD The combination of ramucirumab (Cyramza) and erlotinib (Tarceva) significantly improved progression-free survival (PFS) compared with placebo and erlotinib as a frontline treatment for patients with metastatic EGFR-mutant non...

Leptomeningeal Carcinomatosis: 'A Catastrophic Complication of Breast Cancer'
https://www.staging.medscape.com/viewarticle/928514

May 5th, 2020 - Extending the lifespans of patients with breast cancer with novel therapeutic interventions comes with a downside: It has made patients more susceptible to leptomeningeal carcinomatosis (LC), an increasingly prevalent secondary disease. Estimated ...

see more →